ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 0104 • ACR Convergence 2023

    Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study

    Yin Long1, Jiuliang zhao2, Mengtao Li2, Xinping Tian2 and xiaofeng Zeng3, 1Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, 2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Antiphospholipid antibodies (aPLs) play a pivotal role in the etiology of adverse pregnancy outcomes (APOs). (1) Women with persistently aPLs positivity present heterogeneous clinical…
  • Abstract Number: 1208 • ACR Convergence 2023

    Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study

    Francesca Cardwell1, Alexandra Kobza2, Susan Elliott1, paul Gibson2, Nancy Soliman2, leslie skeith2, Ann Clarke3 and Megan R.W. Barber2, 1University of Waterloo, Waterloo, ON, Canada, 2University of Calgary, Calgary, AB, Canada, 3University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada

    Background/Purpose: Substantial morbidity and mortality affect those with aPLs and APS, yet the patient experience remains poorly understood. This research investigated patient experiences of aPL/APS…
  • Abstract Number: 0105 • ACR Convergence 2023

    Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis

    Yin Long1, Jiuliang zhao2, Mengtao Li2 and Xiaofeng Zeng2, 1Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, 2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by the presence of pathogenic autoantibodies. The key immune cell subsets change in PAPS patients…
  • Abstract Number: 1467 • ACR Convergence 2023

    Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

    Mariana Gonzalez-Trevino1, Jeffrey Yang2, Larry J. Prokop3, Gabriel Figueroa-Parra1 and Ali Duarte-Garcia4, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Internal Medicine, Mayo Clinic, Rochester, MN, 3Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, 4Mayo Clinic, Rochester, MN

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is one of the most devastating complications of SLE. The exact pathogenesis leading to DAH in SLE is not well…
  • Abstract Number: 0106 • ACR Convergence 2023

    Positive Antiphospholipid Antibodies Are Associated with a Higher Risk of Cerebral Microbleeds

    Junna Ye1, Yijun You2, Zhuochao Zhou2, Fan wang2, Jingyi Wu2 and Chengde Yang2, 1Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, 2Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Background/Purpose: Persistent presence of antiphospholipid antibodies (aPLs) are important thrombosis-related laboratory parameters, as well as an indication of anticoagulation use which usually cause higher bleeding…
  • Abstract Number: 1603 • ACR Convergence 2023

    Infection-Associated Antiphospholipid Antibodies and Their Potential Role in Sepsis Outcomes

    Katarina Kmetova, Emily Chong, NaveenKumar K. Somanathapura, Sherwin Navaz, Lyndsay Kluge, Srilakshmi Yalavarthi, Jason Knight, Michael Maile and Yu Zuo, University of Michigan, Ann Arbor, MI

    Background/Purpose: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia characterized by circulating antiphospholipid antibodies (aPL). While the association between aPL and infection has long been…
  • Abstract Number: 0107 • ACR Convergence 2023

    Impact of Antiphospholipid Syndrome on Mortality of Hospitalized Ischemic Stroke Patients: A Retrospective Analysis of the National Inpatient Sample Database 2020

    Sami Rabah, Lincoln Medical Center, New York, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is recognized for its association with an elevated risk of ischemic strokes and other thromboembolic events. This study aims to compare…
  • Abstract Number: 1604 • ACR Convergence 2023

    First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Jonathan Thaler1, Yasaman Ahmadzadeh2, Danieli Andrade3, leslie skeith4, Maria Tektonidou5, Savino Sciascia6, Vittorio Pengo7, Jose Pardos-Gea8, Guillermo Ruiz-Irastorza9, Chary Lopez-Pedrera10, H Michael Belmont11, Kello Nina12, Paul R. Fortin13, Denis WAHL14, Maria Gerosa15, Guilherme De Jesús16, Zhuoli Zhang17, Tatsuya Atsuma18, Maria Efthymiou19, D. Ware Branch20, Laura Andreoli21, Esther Rodriguez almaraz22, Michelle Petri23, Giulia Pazzola24, Ricard Cervera25, Bahar Artim Esen26, Hui Shi27, Jason Knight27, Guillermo Pons-Estel28, Rohan Willis29, Ali Duarte-Garcia30, Maria Laura Bertolaccini31, Hannah Cohen32, Doruk Erkan1 and On Behalf Of APS ACTION33, 1Hospital for Special Surgery, New York, NY, 2Roger Williams Medical Center, Providence, RI, 3University of São Paulo, São Paulo, Brazil, 4University of Calgary, Calgary, AB, Canada, 5Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, 6University of Turin, Torino, Italy, 7Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, 8Vall d'Hebron University Hospital, Barcelona, Spain, 9Hospital Universitario Cruces, Barakaldo, Spain, 10IMIBIC - Reina Sofia Hospital, Córdoba, Spain, 11NYU School of Medicine, New York, NY, 12Northwell Health, Brooklyn, NY, 13Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 14University of Lorraine, Nancy, France, 15University of Milan, Milano, Italy, 16Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 17Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, 18Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, 19University College London, London, United Kingdom, 20University of Utah, Salt Lake City, UT, 21University of Brescia, Brescia, Italy, 22Hospital Universitario 12 de Octubre, Madrid, Spain, 23Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 24Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, 25Hospital Clínic de Barcelona, Barcelona, Spain, 26Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 27University of Michigan, Ann Arbor, MI, 28CREAR, Rosario, Argentina, 29University of Texas Medical Branch, Galveston, TX, 30Mayo Clinic, Rochester, MN, 31King's College London, London, United Kingdom, 32University College London Hospitals NHS Foundation Trust, London, United Kingdom, 33on behalf of APS ACTION, New York, NY

    Background/Purpose: The APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with or…
  • Abstract Number: 0686 • ACR Convergence 2022

    Anti-β2GP1/HLA-DR Antibody Is Associated with Arterial Thrombosis in Female Patients with Connective Tissue Diseases: A Cross-Sectional Study in Japan

    Katsuhiko Yoneda1, Yo Ueda1, Kenji Tanimura2, Hirotaka Yamada1, Takaichi Okano3, Keisuke Nishimura1, Hisashi Arase4, Hideto Yamada5 and Jun Saegusa1, 1Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 2Department of Obstetrics and Gynecology, Kobe University Hospital, Kobe, Japan, 3Kobe University Hospital, Kobe, Japan, 4Department of Immunochemistry, Research Institute for Microbial Disease, Osaka University, Suita, Japan, 5Department of Obstetrics and Gynecology, Kobe University Hospital / Center for Recurrent Pregnancy Loss, Teine Keijinkai Hospital, Sapporo, Japan

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and/or pregnancy complications. Recently, β2-glycoprotein I (β2GPI) complexed with HLA class II molecules (β2GPI/HLA-DR)…
  • Abstract Number: 2268 • ACR Convergence 2022

    Recurrent Thrombosis Risk in Non-anticoagulated Antiphospholipid Syndrome Patients: A Prospective Case-Control Study from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Cecile Yelnik1, Zeynep Belce Erton2, Elodie Drumez3, Dachi Cheildze2, Danieli Castro Oliveira de Andrade4, Ann E Clarke5, Maria G. Tektonidou6, Vittorio Pengo7, Savino Sciascia8, Amaia Ugarte9, H Michael Belmont10, Mª Angeles Aguirre11, Paul fortin12, maria gerosa13, Flavio Victor Signorelli14, Tatsuya Atsumi15, Zhouli Zhang16, Hannah Cohen17, D. Ware Branch18, Denis Wahl19, Laura Andreoli20, Esther Rodriguez Almaraz21, Michelle Petri22, Ricard Cervera23, Yu Zuo24, Bahar Artim-Esen25, Guillermo Pons-Estel26, Rohan Willis27, Maria Laura Bertolaccini28, Robert Roubey29, Doruk Erkan2 and on behalf of APS ACTION On Behalf Of APS ACTION2, 1Lille University, Lille, France, 2Hospital for Special Surgery, New York, NY, 3Université de Lille, Lille, France, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 6National and Kapodistrian University of Athens, Athens, Greece, 7Padova University Hospital, Padova, Italy, 8University of Turin, Torino, Italy, 9BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, 10NYU School of Medicine, New York, NY, 11Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, 12CHU de Québec, Pavillon CHUL, Québec, Canada, 13University of Milan, Milano, Italy, 14Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 15Hokkaido University, Sapporo, Japan, 16Peking University First Hospital, Beijing, China, 17University College London, London, United Kingdom, 18University of Utah, Salt Lake City, UT, 19Université de Nancy, Nancy, France, 20Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 21Hospital Universitario 12 de Octubre, Madrid, Spain, 22Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 23Hospital Clínic de Barcelona, Barcelona, Spain, 24University of Michigan, Ann Arbor, MI, 25Istanbul University, Istanbul, Turkey, 26CREAR, Rosario, Argentina, 27University of Texas Medical Branch, Galveston, TX, 28King's College London, London, United Kingdom, 29University of North Carolina, Chapel Hill, NC

    Background/Purpose: Long-term anticoagulation is the standard of care for antiphospholipid syndrome (APS) patients with macrovascular thrombosis. However, in daily practice, long-term anticoagulation may not be…
  • Abstract Number: 0671 • ACR Convergence 2022

    Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Zeynep Belce Erton1, Rebecca K.Leaf2, Danieli Castro Oliveira de Andrade3, Megan Barber4, Maria G. Tektonidou5, Vittorio Pengo6, Savino Sciascia7, Amaia Ugarte8, H Michael Belmont9, Chary López-Pedrera10, Paul R Fortin11, maria gerosa12, Guilherme de Jesús13, Tatsuya Atsumi14, ZHUOLI ZHANG15, Hannah Cohen16, D. Ware Branch17, Denis WAHL18, Laura Andreoli19, Esther Rodriguez Almaraz20, Michelle Petri21, Ricard Cervera22, Yu (Ray) Zuo23, Bahar Artim-Esen24, 25, Rohan Willis26, Maria Laura Bertolaccini27, Robert Roubey28, Doruk Erkan1 and on behalf of APS ACTION On Behalf Of APS ACTION1, 1Hospital for Special Surgery, New York, NY, 2Massachusetts General Hospital, Boston, MA, 3Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 4Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 5National and Kapodistrian University of Athens, Athens, Greece, 6Padova University Hospital, Padova, Italy, 7University of Turin, Torino, Italy, 8BioCruces Bizkaia Health Research Institute, Barakaldo, Spain, 9NYU School of Medicine, New York, NY, 10Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, 11Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, 12University of Milan, Milano, Italy, 13Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 14Hokkaido University, Sapporo, Japan, 15Peking University First Hospital, Beijing, China, 16University College London Hospitals NHS Foundation Trust, London, United Kingdom, 17University of Utah, Salt Lake City, UT, 18University of Lorraine, Nancy, France, 19Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 20Hospital Universitario 12 de Octubre, Madrid, Spain, 21Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 22Hospital Clinic Barcelona, Barcelona, Spain, 23University of Michigan, Ann Arbor, MI, 24Istanbul University, Istanbul, Turkey, 25Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, 26University of Texas Medical Branch, Galveston, TX, 27King's College London, London, United Kingdom, 28University of North Carolina, Chapel Hill, NC

    Background/Purpose: The APS ACTION Registry was created to study the natural course of antiphospholipid syndrome (APS) over 10 years in persistently antiphospholipid antibody (aPL) positive…
  • Abstract Number: 0687 • ACR Convergence 2022

    DNA- and NET-Binding Beta-2 Glycoprotein I in a Large Cohort of Antiphospholipid Antibody-Positive Patients

    Katarina Kmetova1, Srilakshmi Yalavarthi2, Claire Hoy2, Cyrus Sarosh3, Noah Peters2, Tristin Smith2, Sherwin Navaz2, Yu Zuo2 and Jason S Knight4, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3University of Michigan, Temperance, MI, 4University of Michigan, Division of Rheumatology, Ann Arbor, MI

    Background/Purpose: Beta-2 glycoprotein I (β2GPI) is an abundant plasma protein and a critically important autoantigen in APS. While β2GPI has been reported to have antioxidant,…
  • Abstract Number: 2269 • ACR Convergence 2022

    Anti-NET Antibodies in Antiphospholipid Antibody-positive Patients: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Yu (Ray) Zuo1, Sherwin Navaz1, Alex Tsodikov1, Katarina Kmetova2, Claire Hoy1, Srilakshmi Yalavarthi1, Danieli Castro Oliveira de Andrade3, Maria G. Tektonidou4, Savino Sciascia5, Vittorio Pengo6, Guillermo Ruiz-Irastorza7, H Michael Belmont8, maria gerosa9, Paul fortin10, Guilherme de Jesús11, D. Ware Branch12, Laura Andreoli13, Esther Rodriguez Almaraz14, Michelle Petri15, Ricard Cervera16, Rohan Willis17, Doruk Erkan18 and Jason S Knight19, 1University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 4National and Kapodistrian University of Athens, Athens, Greece, 5University of Turin, Torino, Italy, 6Padova University Hospital, Padova, Italy, 7Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, 8NYU School of Medicine, New York, NY, 9University of Milan, Milano, Italy, 10CHU de Québec, Pavillon CHUL, Québec, Canada, 11Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 12University of Utah, Salt Lake City, UT, 13Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 14Hospital Universitario 12 de Octubre, Madrid, Spain, 15Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 16Hospital Clínic de Barcelona, Barcelona, Spain, 17University of Texas Medical Branch, Galveston, TX, 18Hospital for Special Surgery, New York, NY, 19University of Michigan, Division of Rheumatology, Ann Arbor, MI

    Background/Purpose: The release of neutrophil extracellular traps (NETs) by hyperactive neutrophils plays a role in the thromboinflammatory phenotype of APS. Previous work has demonstrated that…
  • Abstract Number: 0672 • ACR Convergence 2022

    Immune Thrombocytopenia Could Be an Independent Phenotype of Primary Antiphospholipid Syndrome

    Yu Shi1, Jiuliang Zhao2 and Xiaofeng Zeng2, 1Chinese Academy of Medical Sciences, Peking Union Medical College, Dongcheng Qu, China, 2Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: Among patients with immune thrombocytopenia (ITP), 10-30% of them were found with positive antiphospholipid antibodies (aPLs) but without typical clinical manifestations of antiphospholipid syndrome…
  • Abstract Number: 0688 • ACR Convergence 2022

    Antibodies of the IgA Isotype Target Neutrophil Extracellular Traps in APS

    Sherwin Navaz1, Lyndsay Kluge1, Katarina Kmetova2, Bruna Jacintho3, Srilakshmi Yalavarthi1, Claire Hoy1, Cyrus Sarosh4, Noah Peters1, Tristin Smith1, Gabriel Figueroa Parra5, Jacqueline Madison1, Kristen Demoruelle6, Ali Duarte-Garcia5, Jason S Knight7 and Yu (Ray) Zuo1, 1University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3University of Michigan, São Paulo, Brazil, 4University of Michigan, Temperance, MI, 5Mayo Clinic, Rochester, MN, 6University of Colorado Anschutz Medical Campus, Aurora, CO, 7University of Michigan, Division of Rheumatology, Ann Arbor, MI

    Background/Purpose: Neutrophil extracellular traps (NETs) are prothrombotic and proinflammatory webs of nuclear DNA, histones, and microbicidal proteins extruded by neutrophils into the extracellular space in…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology